KS update.
D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004337:Drug Carriers; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin